The company signaled its clinical progress in May by dosing the first patients in a Phase 1 trial for 710GO, its primary candidate for general obesity. This move follows the startup’s emergence from stealth in March, a transition that marked its separation from its former parent, Endevica Bio. Endevica previously secured $10 million in Series B funding in early 2023 to support its research pipeline.
In section Market Quotes
Biotech Startup Kalohexis Initiates Confidential IPO Process
Northbrook-based Kalohexis has moved to join the public markets, filing confidentially for an initial public offering. The biotechnology firm, which spun out of Endevica Bio only months ago, is betting its future on therapies targeting the melanocortin system to treat metabolic conditions, including obesity and cancer cachexia.
Kalohexis confirmed the confidential S-1 submission via a brief press release, withholding financial specifics and the names of underwriters. Further details regarding the company’s capitalization, share structure, and banking partners will emerge once the firm moves to a public filing.
Comments (0)
No comments yet. Be the first!